Q-omics provides the consensus-scored LRRC8D profile across patient tissues and cancer cell-line models. LRRC8D expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC8D is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LRRC8D RNA expression shows 20,035 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where LRRC8D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC8D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC8D survival associations across molecular data types. LRRC8D RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC8D RNA expression–survival associations across cancer types. High LRRC8D expression shows unfavorable associations in ACC, UCEC, KICH, LGG and LIHC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC8D RNA expression.
This table summarizes LRRC8D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC8D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC8D shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, STAD, LIHC and LUSC. The HNSC box plot shows higher LRRC8D RNA expression in tumor versus normal tissue (log2 FC = +1.534, t-test p < 0.001).
This table shows molecular features associated with LRRC8D in patient tissues and cancer cell lines. In patient samples, LRRC8D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC8D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
